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Evidence of Efficacy Is Not
Enough to Develop
Recommendations:
Antibiotics for Treatment
of Traveler’s Diarrhea
To the Editor—In a recent article com-
paring single-dose and 3-day azithromy-
cin-based regimens with a 3-day levoflox-
acin regimen for the treatment of traveler’s
diarrhea, Tribble et al. [1] conclude that
“Single-dose azithromycin is recom-
mended for empirical therapy of traveler’s
diarrhea acquired in Thailand and is a rea-
sonable first-line option for empirical
management in general” (p. 338). We
would like to challenge this statement,
which is based on a small improvement
in the cure rate at 72 h (96% for single-
dose azithromycin and 85% for the 3-day
azithromycin-based regimen, compared
with 71% for the 3-day levofloxacin reg-
imen). We believe that Tribble et al. [1]
do not provide sufficient evidence to sup-
port their conclusions.
First, the study was conducted among
a highly selected population (US military
personnel). The disease was more severe
(17%–31% of patients had documented
fever, and 12%–16% had gross blood in
stools) than in studies conducted among
the standard traveler population [2]. The
enteric pathogens that were recovered and
the pattern of microbial resistance were
not representative of that found in studies
conducted in Thailand and elsewhere in
the world [3]. Moreover, the impact of
concomitant use of doxycycline in 87% of
the patients is unclear. It is obvious that,
therefore, their findings cannot be gen-
eralized to the entire population of
travelers.
Second, they did not include a placebo
arm as a control. This is worrying, espe-
cially when showing that single-dose azith-
romycin had greater efficacy than the 3-
day azithromycin regimen. Without a
placebo group, it is impossible to calculate
the number needed to treat, which is es-
sential to evaluate the benefit of the in-
tervention proposed. The basic assump-
tion of the authors is that antibiotic use
is appropriate in treating traveler’s diar-
rhea. In fact, a Cochrane review showed
that antibiotic use for treatment of trav-
eler’s diarrhea has only a very small benefit
(reducing the duration of diarrhea by 0.7–
1.5 days and the number of loose stools
by 1.6 on the first day of treatment, 2.1
on the second day, and 1.4 on the third
day) [4]. When extrapolating these find-
ings to the general population of travelers,
for every 6 individuals with traveler’s di-
arrhea, 3 will be cured at 72 h if none of
them take antibiotics; 4 of them will be
cured at 72 h if all of them take antibiotics,
at the cost of 1 patient with adverse events.
To develop evidence-based guidelines
for the management of traveler’s diarrhea,
we believe that there is a need to conduct
placebo-controlled effectiveness studies
involving unbiased populations traveling
to different destinations. Even if effective-
ness is demonstrated, this is not enough.
To develop sound recommendations,
there will still be numerous questions that
need to be answered, such as: is there any
clear benefit to treating traveler’s diarrhea
at an early stage? Does the small benefit
associated with antibiotic treatment of
clinical symptoms outweigh the risk of ad-
verse events? Is it worth giving antibiotics
to travelers when there is good proof that,
in vivo, these drugs select drug-resistant
pathogens in the gut flora? Why should
traveler’s diarrhea be treated with antibi-
otics, given the demonstration that pa-
tients with drug-resistant enteropathogens
have clinical outcomes similar to those
with fully susceptible enteropathogens?
What is the impact of large-scale (irra-
tional) use of antibiotics on the dynamics
of bacterial resistance in host countries,
given that such countries cannot afford
expensive drugs to manage multidrug-re-
sistant pathogens? Lastly, why should
travel medicine experts continue to ignore
World Health Organization recommen-
dations that restrict antibiotic use to pa-
tients with increased risk of complications
or with signs of severe disease? Unless
these issues are addressed in an unbiased
way, we will continue to have recommen-
dations that rely on low-quality evidence
and are based on expert opinions or—
even worse—on commercial interest.
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